MediWound (NASDAQ:MDWD) Stock Price Passes Below 200 Day Moving Average – Here’s Why

Posted by Geri Gentry on Sep 17th, 2026

MediWound Ltd. (NASDAQ:MDWD – Get Free Report) shares passed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $15.27 and traded as low as $13.19. MediWound shares last traded at $13.47, with a volume of 80,527 shares.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the stock. Weiss Ratings downgraded shares of MediWound from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, September 8th. Alliance Global Partners reiterated a “buy” rating on shares of MediWound in a research report on Wednesday. Oppenheimer reissued an “outperform” rating and set a $30.00 target price (down from $32.00) on shares of MediWound in a research note on Friday, August 14th. Wall Street Zen cut MediWound from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 15th. Finally, HC Wainwright reiterated a “buy” rating and set a $36.00 price target on shares of MediWound in a report on Thursday, May 28th. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $33.00.

View Our Latest Analysis on MediWound

MediWound Price Performance

The stock has a market capitalization of $171.55 million, a P/E ratio of -7.42 and a beta of 0.14. The stock’s fifty day moving average is $13.77 and its 200-day moving average is $15.24.

MediWound (NASDAQ:MDWD – Get Free Report) last posted its earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.77) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.01). MediWound had a negative net margin of 170.10% and a negative return on equity of 47.24%. The firm had revenue of $3.09 million during the quarter, compared to analyst estimates of $2.59 million. On average, research analysts expect that MediWound Ltd. will post -2.31 EPS for the current year.

Insider Activity

In related news, COO Shmuel Hess sold 3,958 shares of the stock in a transaction dated Thursday, August 27th. The shares were sold at an average price of $12.92, for a total value of $51,137.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 9.20% of the company’s stock.

Institutional Investors Weigh In On MediWound

A number of large investors have recently bought and sold shares of the business. Silverberg Bernstein Capital Management LLC lifted its position in shares of MediWound by 8.7% during the first quarter. Silverberg Bernstein Capital Management LLC now owns 200,005 shares of the biopharmaceutical company’s stock worth $3,222,000 after purchasing an additional 16,081 shares in the last quarter. UBS Group AG grew its holdings in MediWound by 90.1% during the 4th quarter. UBS Group AG now owns 145,057 shares of the biopharmaceutical company’s stock worth $2,678,000 after acquiring an additional 68,756 shares during the period. Finally, Clal Insurance Enterprises Holdings Ltd lifted its stake in shares of MediWound by 22.8% in the 4th quarter. Clal Insurance Enterprises Holdings Ltd now owns 71,000 shares of the biopharmaceutical company’s stock valued at $1,311,000 after purchasing an additional 13,196 shares during the period. 46.83% of the stock is currently owned by institutional investors.

About MediWound

(Get Free Report)

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative enzymatic therapies for tissue injury and wound care. The company’s products are designed to remove damaged or nonviable tissue while helping preserve healthy tissue, supporting wound management and healing.

MediWound’s lead commercial product is NexoBrid, a topical bromelain-based therapy used for the enzymatic removal of eschar in adults with deep partial-thickness and full-thickness thermal burns.